Leerink Partnrs Comments on Genmab A/S FY2027 Earnings

Key Points

• Analysts at Leerink Partners projected a FY2027 earnings per share (EPS) of $1.13 for Genmab A/S, which is below the current consensus estimate of $1.45.
• Genmab A/S has received a mix of ratings from brokerages, with a range of strong-buy to sell ratings, reflecting varying opinions on the stock's future performance.
• As of the latest trading session, Genmab A/S shares were up 3.6%, showing an increasing trend from a yearly low of $17.24 to a high of $31.82.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Genmab A/S in a research note issued on Monday, September 29th. Leerink Partnrs analyst J. Chang expects that the company will post earnings per share of $1.13 for the year. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Several other brokerages have also commented on GMAB. Truist Financial upped their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Zacks Research downgraded shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Guggenheim upgraded shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price on the stock in a research report on Tuesday, September 23rd. Wall Street Zen raised shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. Finally, HC Wainwright upped their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and an average target price of $40.00.

Genmab A/S Trading Up 3.6%

Shares of Genmab A/S stock opened at $31.77 on Thursday. The business has a 50-day moving average price of $25.47 and a two-hundred day moving average price of $22.26. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $31.82. The company has a market cap of $20.38 billion, a P/E ratio of 15.96, a PEG ratio of 1.75 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Trading of Genmab A/S

A number of large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in Genmab A/S by 1,465.3% in the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after acquiring an additional 31,343 shares during the last quarter. Park Avenue Securities LLC bought a new stake in shares of Genmab A/S in the 1st quarter worth approximately $276,000. Fifth Third Bancorp lifted its stake in Genmab A/S by 16.6% in the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock valued at $825,000 after purchasing an additional 6,015 shares during the last quarter. QRG Capital Management Inc. grew its holdings in Genmab A/S by 213.7% during the first quarter. QRG Capital Management Inc. now owns 74,847 shares of the company's stock valued at $1,465,000 after purchasing an additional 50,990 shares during the period. Finally, Blue Trust Inc. increased its position in Genmab A/S by 169.9% in the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after buying an additional 4,666 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.